About: Ramelteon

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ramelteon Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/drugbank/Drug, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/drugbank/Drug
http://linked.open...gbank/description	Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. (en)
http://linked.open...y/drugbank/dosage	http://linked.opendata.cz/resource/drugbank/dosage/271B4881-363D-11E5-9242-09173F13E4C5
http://linked.open...generalReferences	# Karim A, Tolbert D, Cao C: Disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia. J Clin Pharmacol. 2006 Feb;46(2):140-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16432265 # Miyamoto M: Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009 Winter;15(1):32-51. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19228178 # Pandi-Perumal SR, Srinivasan V, Spence DW, Moscovitch A, Hardeland R, Brown GM, Cardinali DP: Ramelteon: a review of its therapeutic potential in sleep disorders. Adv Ther. 2009 Jun;26(6):613-26. Epub 2009 Jun 30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19568703 # Borja NL, Daniel KL: Ramelteon for the treatment of insomnia. Clin Ther. 2006 Oct;28(10):1540-55. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17157111 # Roth T, Stubbs C, Walsh JK: Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep. 2005 Mar 1;28(3):303-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16173650 # Simpson D, Curran MP: Ramelteon: a review of its use in insomnia. Drugs. 2008;68(13):1901-19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18729542 (en)
http://linked.open...gy/drugbank/group	approved (en) investigational (en)
http://linked.open...drugbank/halfLife	~1-2.6 hours (en)
http://linked.open...ugbank/indication	For the treatment of insomnia characterized by difficulty with sleep onset. (en)
http://linked.open...bank/manufacturer	A-S Medication Solutions LLC
sameAs	Ramelteon Ramelteon
Title	Ramelteon (en)
adms:identifier	http://linked.opendata.cz/resource/drugbank/drug/DB00980/identifier/bindingdb/50118470 http://linked.opendata.cz/resource/drugbank/drug/DB00980/identifier/chemspider/181000 http://linked.opendata.cz/resource/drugbank/drug/DB00980/identifier/drugbank/DB00980 http://linked.opendata.cz/resource/drugbank/drug/DB00980/identifier/guide-to-pharmacology/1356 http://linked.opendata.cz/resource/drugbank/drug/DB00980/identifier/iuphar/1356 http://linked.opendata.cz/resource/drugbank/drug/DB00980/identifier/national-drug-code-directory/64764-805-30 http://linked.opendata.cz/resource/drugbank/drug/DB00980/identifier/pubchem-compound/208902 http://linked.opendata.cz/resource/drugbank/drug/DB00980/identifier/pubchem-substance/46505923 http://linked.opendata.cz/resource/drugbank/drug/DB00980/identifier/pharmgkb/PA164744896 http://linked.opendata.cz/resource/drugbank/drug/DB00980/identifier/wikipedia/Ramelteon
http://linked.open...mechanismOfAction	Ramelteon is a melatonin receptor agonist with both high affinity for melatonin MT<sub>1</sub> and MT<sub>2</sub> receptors, and lower selectivity for the MT<sub>3</sub> receptor. Melatonin production is concurrent with nocturnal sleep, meaning that an increase in melatonin levels is related to the onset of self-reported sleepiness and an increase in sleep propensity. MT<sub>1</sub> receptors are believed to be responsible for regulation of sleepiness and facilitation of sleep onset, and MT<sub>2</sub> receptors are believed to mediate phase-shifting effects of melatonin on the circadian rhythm. While MT<sub>1</sub> and MT<sub>2</sub> receptors are associated with the sleep-wake cycle, MT<sub>3</sub> has a completely different profile, and therefore is not likely to be involved in the sleep-wake cycle. Remelteon has no appreciable affinity for the gamma-aminobutyric acid (GABA) receptor complex or receptors that bind neuropeptides, cytokines, serotonin, dopamine, norepinephrine, acetylcholine, or opiates. (en)
http://linked.open...drugbank/packager	Advanced Pharmaceutical Services Inc. Bryant Ranch Prepack DispenseXpress Inc. Amerisource Health Services Corp. A-S Medication Solutions LLC Bryant Ranch Prepack Apothecon
http://linked.open...y/drugbank/patent	http://linked.opendata.cz/resource/drugbank/patent/6034239
http://linked.open...outeOfElimination	Following oral administration of radiolabeled ramelteon, 84% of total radioactivity was excreted in urine and approximately 4% in feces, resulting in a mean recovery of 88%. Less than 0.1% of the dose was excreted in urine and feces as the parent compound. (en)
http://linked.open.../drugbank/synonym	Rozerem (en)
http://linked.open...umeOfDistribution	* 73.6 L (en)
http://linked.open...k/foodInteraction	Avoid alcohol. (en) Do not take with or immediately after a high-fat meal. (en)
http://linked.open...nk/proteinBinding	~82% (in human serum) (en)
http://linked.open...ynthesisReference	Vinod Kumar Kansal, Dhirenkumar N. Mistry, Sanjay L. Vasoya, "Intermediates and processes for the synthesis of Ramelteon." U.S. Patent US20080242877, issued October 02, 2008. (en)
http://linked.open...y/mesh/hasConcept	http://linked.opendata.cz/resource/mesh/concept/M0480272
foaf:page	http://www.drugs.com/cdi/ramelteon.html http://www.rxlist.com/cgi/generic4/rozerem.htm
http://linked.open...ugbank/IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4886-363D-11E5-9242-09173F13E4C5
http://linked.open...gy/drugbank/InChI	http://linked.opendata.cz/resource/drugbank/property/271B488C-363D-11E5-9242-09173F13E4C5
http://linked.open...Molecular-Formula	http://linked.opendata.cz/resource/drugbank/property/271B488B-363D-11E5-9242-09173F13E4C5
http://linked.open.../Molecular-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4888-363D-11E5-9242-09173F13E4C5
http://linked.open...noisotopic-Weight	http://linked.opendata.cz/resource/drugbank/property/271B4889-363D-11E5-9242-09173F13E4C5
http://linked.open...y/drugbank/SMILES	http://linked.opendata.cz/resource/drugbank/property/271B488A-363D-11E5-9242-09173F13E4C5
http://linked.open.../Water-Solubility	http://linked.opendata.cz/resource/drugbank/property/271B4884-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logP	http://linked.opendata.cz/resource/drugbank/property/271B4882-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B4885-363D-11E5-9242-09173F13E4C5 http://linked.opendata.cz/resource/drugbank/property/271B489C-363D-11E5-9242-09173F13E4C5
http://linked.open...ogy/drugbank/logS	http://linked.opendata.cz/resource/drugbank/property/271B4883-363D-11E5-9242-09173F13E4C5
http://linked.open...l/drug/hasATCCode	Ramelteon
http://linked.open...nd-Acceptor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4892-363D-11E5-9242-09173F13E4C5
http://linked.open...-Bond-Donor-Count	http://linked.opendata.cz/resource/drugbank/property/271B4893-363D-11E5-9242-09173F13E4C5
http://linked.open...drugbank/InChIKey	http://linked.opendata.cz/resource/drugbank/property/271B488D-363D-11E5-9242-09173F13E4C5
http://linked.open...urface-Area--PSA-	http://linked.opendata.cz/resource/drugbank/property/271B488E-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/Polarizability	http://linked.opendata.cz/resource/drugbank/property/271B4890-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Refractivity	http://linked.opendata.cz/resource/drugbank/property/271B488F-363D-11E5-9242-09173F13E4C5
http://linked.open...atable-Bond-Count	http://linked.opendata.cz/resource/drugbank/property/271B4891-363D-11E5-9242-09173F13E4C5
http://linked.open...ugbank/absorption	Rapid, total absorption is at least 84%. (en)
http://linked.open.../affectedOrganism	Humans and other mammals (en)
http://linked.open...casRegistryNumber	196597-26-9 (en)
http://linked.open...gbank/containedIn	Rozerem 8 mg tablet
http://linked.open...k/Bioavailability	http://linked.opendata.cz/resource/drugbank/property/271B4898-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Ghose-Filter	http://linked.opendata.cz/resource/drugbank/property/271B489A-363D-11E5-9242-09173F13E4C5
http://linked.open...nk/MDDR-Like-Rule	http://linked.opendata.cz/resource/drugbank/property/271B489B-363D-11E5-9242-09173F13E4C5
http://linked.open...k/Number-of-Rings	http://linked.opendata.cz/resource/drugbank/property/271B4897-363D-11E5-9242-09173F13E4C5
http://linked.open...siological-Charge	http://linked.opendata.cz/resource/drugbank/property/271B4896-363D-11E5-9242-09173F13E4C5
http://linked.open...bank/Rule-of-Five	http://linked.opendata.cz/resource/drugbank/property/271B4899-363D-11E5-9242-09173F13E4C5
http://linked.open...tional-IUPAC-Name	http://linked.opendata.cz/resource/drugbank/property/271B4887-363D-11E5-9242-09173F13E4C5
http://linked.open...strongest-acidic-	http://linked.opendata.cz/resource/drugbank/property/271B4894-363D-11E5-9242-09173F13E4C5
http://linked.open...-strongest-basic-	http://linked.opendata.cz/resource/drugbank/property/271B4895-363D-11E5-9242-09173F13E4C5

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 37 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software